

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 2nd August 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Tirbanibulin (Klisyri@▼, Almirall) 10mg/g ointment			✓	Requested for field treatment of non-hyperkeratotic, non hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. Decision: decision deferred to confirm place in therapy by request for a pathway/guideline, and that use by primary care is preferable to reduce requirements for referral to secondary care. Also can Diclofenac be removed from the treatment pathway
2) New Requests				
None				
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA894: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemo-immunotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA896: Bulevirtide for treating chronic hepatitis D	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA899: Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)				The formulary will reflect the TAG – ICS is the responsible commissioner. Received for information.
TA900: Tixagevimab plus cilgavimab for preventing COVID-19	✓ BLACK			The formulary will reflect the TAG – ICS is the responsible commissioner.
TA901: Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	✓ ASR			The formulary will reflect the TAG – ICS is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA906: Rimegepant for preventing migraine			✓	
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
None				

The following documents/guidelines were presented to and approved at the August 2023 meeting of the APC:

- HNY Type 2 Diabetes Algorithm Final
- HNY ICB CGM policy
- NY&Y Guidance on managing seizures in palliative patients
- NY&Y Guidelines for recognition and management of non- IgE cow's milk allergy in children – updated
- NY&Y Biologics Pathway for Psoriasis – updated
- NY&Y Formulary harmonisation - Chapter 12: Ear, Nose and Oropharynx

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the August 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the August 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the August 2023 meeting of the APC for comment:

- Diazoxide for treating intractable hypoglycaemia for adult patients within Endocrinology shared care guideline.